Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Ping-Ching Hsu to Drug Therapy, Combination

This is a "connection" page, showing publications Ping-Ching Hsu has written about Drug Therapy, Combination.

 
Connection Strength
  
 
 
0.827
  
  1. Hsu PI, Chen KY, Tai WC, Yang JC, Tsay FW, Liu YH, Chen CL, Lee CL, Yeh HZ, Kuo CH, Chuah SK, Lee HC, Shie CB, Shiu SI, Kao JY, Yamaoka Y, Graham DY, Wu DC. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
    View in: PubMed
    Score: 0.180
  2. Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter. 2021 Oct; 26(5):e12840.
    View in: PubMed
    Score: 0.161
  3. Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018 Aug; 23(4):e12498.
    View in: PubMed
    Score: 0.130
  4. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, Tsay FW, Wu CJ, Lo CC, Tseng HH, Yamaoka Y, Chen JL, Lo GH. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005 Nov; 100(11):2387-92.
    View in: PubMed
    Score: 0.054
  5. Wu PJ, Tsay FW, Wu DC, Yang JC, Chuah SK, Chen KY, Chen CL, Lee CL, Shih CA, Liu YH, Shiu SI, Tai WC, Kuo CH, Lei WY, Kao SS, Tsai TJ, Feng IC, Koseki M, Hsu PI, Sheu MJ. Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024. World J Gastroenterol. 2025 Oct 21; 31(39):111380.
    View in: PubMed
    Score: 0.054
  6. Chuah YY, Wu DC, Chuah SK, Chen KY, Yang JC, Lee CL, Chen CL, Shiu SI, Shie CB, Shih CA, Tsay FW, Liu YH, Hsu PI. REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020. Helicobacter. 2022 Dec; 27(6):e12931.
    View in: PubMed
    Score: 0.044
  7. Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020 09; 7(1).
    View in: PubMed
    Score: 0.038
  8. Wu CK, Liang CM, Hsu CN, Hung TH, Yuan LT, Nguang SH, Wang JW, Tseng KL, Ku MK, Yang SC, Tai WC, Shih CW, Hsu PI, Wu DC, Chuah SK. The Role of Adjuvant Acid Suppression on the Outcomes of Bleeding Esophageal Varices after Endoscopic Variceal Ligation. PLoS One. 2017; 12(1):e0169884.
    View in: PubMed
    Score: 0.029
  9. Wang JW, Hsu CN, Tai WC, Ku MK, Hung TH, Tseng KL, Yuan LT, Nguang SH, Liang CM, Yang SC, Wu CK, Hsu PI, Wu DC, Chuah SK. The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases. PLoS One. 2016; 11(10):e0164824.
    View in: PubMed
    Score: 0.029
  10. Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother. 2013 Jan; 68(1):222-8.
    View in: PubMed
    Score: 0.022
  11. Lin KH, Hsu PI, Yu HC, Lin CK, Tsai WL, Chen WC, Chan HH, Lai KH. Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts. BMC Gastroenterol. 2012 Jan 18; 12:7.
    View in: PubMed
    Score: 0.021
  12. Wu DC, Hsu PI, Tseng HH, Tsay FW, Lai KH, Kuo CH, Wang SW, Chen A. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore). 2011 May; 90(3):180-185.
    View in: PubMed
    Score: 0.020
  13. Chen TA, Tsao YC, Chen A, Lo GH, Lin CK, Yu HC, Cheng LC, Hsu PI, Tsai WL. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol. 2009; 44(5):619-25.
    View in: PubMed
    Score: 0.017
  14. Lo GH, Chen WC, Lin CK, Tsai WL, Chan HH, Chen TA, Yu HC, Hsu PI, Lai KH. Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology. 2008 Aug; 48(2):580-7.
    View in: PubMed
    Score: 0.016
  15. Wu CJ, Hsu PI, Lo GH, Lo CC, Lin CK, Shie CB, Peng NJ, Tseng HH, Jou HS, Tsai PM, Chen A, Chen JL, Lai KH. Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J Chin Med Assoc. 2004 Apr; 67(4):161-7.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.